| Literature DB >> 24371760 |
Mutende J Sikuyayenga1, Craig B Reeder1, Joseph R Mikhael1.
Abstract
Multiple Myeloma and Mantle Cell Lymphoma are well defined hematological malignancies. Understanding of their pathogeneses has led to new therapies and increased survival. We report on a 64-yr-old female who was diagnosed with mantle cell lymphoma in 2003, then multiple myeloma in 2010. We identified only few other cases of concomitant MM and MCL. We also explored the importance of t(11;14)(q13;q32). The development of these two disorders in the same patient may simply be due to chance; however, it may also represent a common genetic hit affecting the B-cell population leading to development of two different malignancies.Entities:
Keywords: FDG, fluorodeoxyglucose; G-CSF, granulocyte colony-stimulating factor; IgH, immunoglobin heavy (chain); MCL, mantle cell lymphoma; MM, multiple myeloma; Mantle cell lymphoma; Multiple myeloma; PBSCT, peripheral blood stem cell transplantation; VCD, velcade (bortezomib) cyclophosphamide dexamethasone; VDJ, variable, diverse, joining (region); VRD, velcade revlimid (lenalidomide) dexamethasone; t(11;14)(q13;q32)
Year: 2012 PMID： 24371760 PMCID： PMC3787821 DOI： 10.1016/j.lrr.2012.09.003
Source DB: PubMed Journal: Leuk Res Rep ISSN： 2213-0489